ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer
July 20th 2022Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.